Annovis Bio Inc. (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy buntanetap for Alzheimer's and Parkinson's diseases, announced that Founder, President and CEO Maria Maccecchini, Ph.D., will participate in two industry conferences in November. The presentations matter because they give the company a platform to detail its clinical progress and upcoming milestones to investors, pharmaceutical partners and industry peers at a time when neurodegenerative disease treatments remain a high-priority area for drug developers.
At U.S. Biotech Day 2026, scheduled for Nov. 16-17 in Philadelphia, Maccecchini will join a panel discussion titled “Bridging the Translational Gap: From Discovery Insights to Clinical Proof” on Nov. 16 from 9:15-9:45 a.m. ET, followed by a company presentation from 10:15-10:30 a.m. ET highlighting Annovis’ clinical programs and upcoming milestones. The panel topic is significant because it addresses one of the central challenges in biotechnology: moving early discovery findings into human trials that demonstrate real clinical benefit. For Annovis, the presentation offers a chance to position buntanetap within that translational conversation as the company advances its Phase 3 work.
Maccecchini will also present at Pharma Partnering Summit 2026, scheduled for Nov. 19-20 in Boston. Her presentation, titled “Restoring Proteostasis in Alzheimer’s and Parkinson’s Diseases with Buntanetap, a Translational Inhibitor of Neurotoxic Proteins,” will take place Nov. 19 from 11:25-11:55 a.m. ET. The title points to the company’s core scientific thesis: that buntanetap works by inhibiting the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein and TDP-43, through a specific RNA-targeting mechanism. By addressing underlying causes of neurodegeneration rather than only symptoms, Annovis aims to halt disease progression and improve cognitive and motor functions in patients.
During both events, Maccecchini will hold one-on-one meetings with biotechnology and pharmaceutical industry representatives to discuss the company’s clinical progress and potential opportunities. Those meetings are important because they can open doors to collaboration, licensing or other strategic relationships that may help fund and accelerate development. For a clinical-stage company, such partnering conversations are often as consequential as the data itself.
Annovis Bio is headquartered in Malvern, Pennsylvania, and its lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy. The company’s approach targets multiple neurotoxic proteins simultaneously, a differentiated strategy in a field where many programs focus on a single protein. If the approach succeeds in late-stage trials, it could have implications for how Alzheimer’s and Parkinson’s are treated, though the company remains in the clinical stage and no therapy has yet been approved.
Investors seeking more detail can view the full press release at https://ibn.fm/0D5yA and find additional information on the company’s website at www.annovisbio.com. The company also maintains a presence on LinkedIn, YouTube, and X, and the latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS. The announcement was distributed with support from MissionIR, which is part of the Dynamic Brand Portfolio at IBN and provides services including InvestorWire distribution and editorial syndication to 5,000+ outlets.
